John W. Walker

Dr. John W. Walker


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Clinical Nutrition
Verified
Journal Article
Closed access
MSMartine Jane Sealy
Martine Jane Sealy
TDTanadech Dechaphunkul
Tanadech Dechaphunkul
CSCees P. van der Schans
Cees P. van der Schans
WKWim P. Krijnen
Wim P. Krijnen
JRJan L.N. Roodenburg
Jan L.N. Roodenburg
Vickie Elaine BaracosVickie Elaine Baracos
Vickie Elaine Baracos

2 February 2023 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
CYCarrie Ye
Carrie Ye
KLKevin Lee
Kevin Lee
WLWilliam D. Leslie
William D. Leslie
MLMu Lin
Mu Lin
JWJohn W. Walker
John W. Walker
MKMichael Kolinsky
Michael Kolinsky

22 February 2024 in Clinical Nutrition
Verified
Journal Article
Open access
CKCatherine Kubrak
Catherine Kubrak
LMLisa Martin
Lisa Martin
AGAaron J Grossberg
Aaron J Grossberg
BOBrennan Olson
Brennan Olson
FOFaith Ottery
Faith Ottery
Vickie Elaine BaracosVickie Elaine Baracos
Vickie Elaine Baracos
Existing skeletal muscle index (SMI) thresholds for sarcopenia are inconsistent, and do not reflect severity of depletion. In this study we aimed to define criterion values for moderate and severe skeletal muscle depletion based on the risk of mortality in a population of patients with head and neck cancer (HNC). Additionally, we aimed to identify clinical and demographic predictors of skeletal muscle depletion, evaluate the survival impact of skeletal muscle depletion in patients with minimal nutritional risk or good performance status, and finally, benchmarking SMI values of patients with HNC against healthy young adults. Population cohort of 1231 consecutive patients and external validation cohorts with HNC had lumbar SMI measured by cross-sectional imaging. Optimal stratification determined sex-specific thresholds for 2-levels of SMI depletion (Class I and II) based on overall survival (OS). Adjusted multivariable regression analyses (tumor site, stage, performance status, age, sex, dietary intake, weight loss) determined relationships between 2-levels of SMI depletion and OS. Mean SMI (cm2/m2) was 51.7 ± 9.9 (males) and 39.8 ± 7.1 (females). The overall and sex-specific population demonstrated an increased risk of mortality associated with decreasing SMI. Sex-specific SMI (cm2/m2) depletion thresholds for 2-levels of muscle depletion determined by optimal stratification for males and females, respectively (male: 45.2-37.5, and <37.5; female: 40.9-34.2, and <34.2). In the overall population, Normal SMI, Class I and II SMI depletion occurred in 65.0%, 24.0%, and 11.0%, respectively. Median OS was: Normal SMI (114 months, 95% CI, 97.1-130.8); Class I SMI Depletion (42 months, 95% CI, 28.5-55.4), and Class II SMI Depletion (15 months, 95% CI, 9.8-20.1). Adjusted multivariable analysis compared with Normal SMI (reference), Class I SMI Depletion (HR, 1.49; 95% CI, 1.18-1.88; P < .001), Class II SMI Depletion (HR, 1.91; 95% CI, 1.42-2.58; P < .001). Moderate and severe SMI depletion demonstrate discrimination in OS in patients with HNC. Moderate and severe SMI depletion is prevalent in patients with minimal nutrition risk and good performance status. Benchmarking SMI values against healthy young adults exemplifies the magnitude of SMI depletion in patients with HNC and may be a useful method in standardizing SMI assessment.

1 June 2025 in Canadian Medical Association Journal
Verified
Journal Article
Open access
OAOmar Abdel-Rahman
Omar Abdel-Rahman
EMEthan McFarlane
Ethan McFarlane
HOHyejee Ohm
Hyejee Ohm
ACAngela Chan
Angela Chan
SLShaun Loewen
Shaun Loewen
JWJohn W. Walker
John W. Walker

24 January 2025 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
BMBryn E Matheson
Bryn E Matheson
JJJacob Lester Jaremko
Jacob Lester Jaremko
ADAlexandra Dowhanik
Alexandra Dowhanik
JGJasmine Gill
Jasmine Gill
CGCassandra Gallant
Cassandra Gallant
CYCarrie Ye
Carrie Ye
Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, yet their impact on bone health remains unclear. This study aimed to perform a retrospective cohort study utilizing routine CT scans from patients with melanoma to perform opportunistic QCT analysis to investigate the effects of ICI treatment on skeletal health, including volumetric BMD (vBMD) measurements and osteoarthritis (OA) parameters. A previously established machine learning-assisted opportunistic QCT pipeline was used to estimate lumbar spine vBMD from baseline and 12-mo follow-up CT scans in patients with melanoma treated with ICI therapy and those not treated with ICI therapy. Facet joint OA, osteophyte formation, and endplate sclerosis were also graded. Independent and paired t tests were used to determine any differences in vBMD and OA parameters between ICI users and non-ICI users. Multivariable linear regression models were used to control for confounding variables. Non-ICI users had a significant decrease in vBMD of −6.96 mg/cm3 from baseline to follow-up, whereas the ICI users had no significant change. There was a significant difference in change in vBMD from baseline to follow-up between the 2 groups, with the non-ICI users experiencing a 11.22 mg/cm3 larger decrease in vBMD. After adjusting for baseline age, sex, baseline vBMD, and change in OA parameters, this difference remained significant at −13.04 mg/cm3. Among the ICI users, those who had a decline in vBMD had a lower baseline vBMD compared with those who had increased vBMD. Neither group showed a significant change in OA parameters over the follow-up period, nor a difference in change between ICI and non-ICI users, even after adjusting for sex, age, and baseline OA parameters. While the effects of ICI treatment on vBMD may vary based on baseline bone health, ICIs do not significantly impact OA parameters in the short term.

7 October 2023 in BioMedInformatics
Verified
Journal Article
Open access
PDF file
UCUtkarsh Chauhan
Utkarsh Chauhan
KZKaiqiong Zhao
Kaiqiong Zhao
JWJohn W. Walker
John W. Walker
JMJohn Robert Mackey
John Robert Mackey
The Kaplan–Meier (KM) estimator is widely used in medical research to estimate the survival function from lifetime data. KM estimation is a powerful tool to evaluate clinical trials due to simple computational requirements, its use of a logrank hypothesis test, and the ability to censor patients. However, KM estimation has several constraints and fails to generalize to ordinal variables of clinical interest, such as toxicity and ECOG performance. We devised weighted trajectory analysis (WTA) to combine the advantages of KM estimation with the ability to visualize and compare treatment groups for ordinal variables and fluctuating outcomes. To assess statistical significance, we developed a new hypothesis test analogous to the logrank test. We demonstrated the functionality of WTA through 1000-fold clinical trial simulations of unique stochastic models of chemotherapy toxicity and schizophrenia disease course. With increments in sample size and hazard ratio, we compared the performance of WTA to KM estimation and the generalized estimating equation (GEE). WTA generally required half the sample size to achieve comparable power to KM estimation; advantages over the GEE included its robust nonparametric approach and summary plot. We also applied WTA to real clinical data: the toxicity outcomes of melanoma patients receiving immunotherapy and the disease progression of patients with metastatic breast cancer receiving ramucirumab. The application of WTA demonstrated that using traditional methods such as KM estimation can lead to both type I and II errors by failing to model illness trajectory. This article outlines a novel method for clinical outcome assessment that extends the advantages of Kaplan–Meier estimates to ordinal outcome variables.